Abbott Presents Improved MRD Test Sensitivity for Colorectal Cancer Recurrence
What happened
Abbott announced new Beta-CORRECT study results presented at the European Society for Medical Oncology Congress. The study showed that Abbott's whole-genome sequencing (WGS)-based Oncodetect® molecular residual disease (MRD) test achieved a 30-percent absolute improvement in sensitivity for colorectal cancer recurrence within two years of surgery, compared with the whole-exome sequencing (WES) Oncodetect test, using a single post-surgery blood draw. The research was conducted in collaboration with Dr. Takayuki Yoshino and National Cancer Center Hospital East in Japan.
From prnewswire.com
Why it matters
The results reflect Abbott's effort to connect innovations across the cancer care continuum, expanding from its Cologuard® screening test to post-treatment monitoring. This advancement in diagnostic tools could influence the demand for advanced cancer recurrence monitoring services.
From prnewswire.com
Who's involved
- European Society for Medical OncologyHosted the European Society for Medical Oncology Congress where the findings were presented.
- Takayuki YoshinoResearcher who collaborated with Abbott on the Beta-CORRECT study.
- National Cancer Center Hospital EastHospital in Japan where Dr. Takayuki Yoshino conducted the study.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- TempusSpeculative
Abbott's validated MRD test might strengthen its competitive position in diagnostics, potentially affecting Tempus's market share.
- National Cancer Center Hospital EastSpeculative
The successful clinical validation study might enhance the hospital's research reputation, potentially attracting future funding.
Keep exploring
The entities involved
-
European Society for Medical Oncology
Professional organisation
-
Takayuki Yoshino
researcher (ORCID 0000-0002-0489-4756)
Nothing else this week.
-
National Cancer Center Hospital East
hospital in Kashiwa, Japan
Nothing else this week.
Related events
- Hengrui Pharma and Guangdong Provincial People's Hospital presented research findings at the ESMO Congress on October 20, 2026.
- Eli Lilly and Company presented oncology data at the European Society for Medical Oncology (ESMO) Congress.
- Bristol-Myers Squibb presented clinical data at the European Society for Medical Oncology (ESMO) Congress in Madrid.
- Zai Lab presented data at a meeting in Barcelona, involving researcher Pedro Rocha and Amgen.
- Study results were presented by Tempus and Pfizer at the ESMO Congress, focusing on ongoing collaboration regarding diagnostic barriers.